Trans-Pyrenean Network for Advanced Therapies in Non-Hodgkin Lymphoma

Published on September 29, 2025 – Updated on October 13, 2025

THERAVLINFO represents an advance in the biomedical translation of knowledge and preclinical lymphoma models generated in IMLINFO (EFA 281/16), aimed at improving survival and quality of life for patients with this haematological cancer.

THERAVLINFO is a multidisciplinary network that aims to strengthen cooperation among four previous partners (two hospitals and two research centres in Barcelona and Toulouse) and to foster new synergies with one research centre in Navarre. It also collaborates with two biotechnology companies within the POCTEFA region.

A previous project, entitled IMLINFO, established a biobank of samples from patients with non-Hodgkin lymphoma (NHL), developed a 3D culture platform that models the disease in vitro, and created a workflow for antitumor drug screening. Targets involved in evading the antitumor immune response and in immunosuppression were also identified.
  • THERAVLINFO will enhance the 3D systems, develop drugs against these targets (antibodies, CAR-T cell therapy, and nanocapsules), and validate their therapeutic potential in murine models.
  • THERAVLINFO involves the cooperation of experts in 3D multicellular cultures, animal models, multiparametric cytometry, confocal microscopy, omics technologies, and computational analysis, and aims to promote the training of young researchers capable of integrating and rotating among the cross-border partners.
  • THERAVLINFO develops cellular therapies with the Hospital Clínic of Barcelona and promotes collaborations with companies for the development of immunotherapies using antibodies (ONA Therapeutics) and new systems for antibody bioavailability and oral delivery (NUCAPS).
To advance towards personalised medicine for patients with NHL who do not respond to standard treatment, experience early relapse, or progress to aggressive lymphoma, cross-border cooperation is essential to obtain material from these patients in hospitals and to develop new therapies.

Partners:
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, FRCB-IDIBAPS (Barcelone)
- Hospital Clínico de Barcelona, HCB (Barcelone)
- Université Toulouse III - Paul Sabatier UT3 (Haute Garonne)
- Centre Hospitalier Universitaire de Toulouse, CHUT (Haute Garonne)
- Universidad de Navarra, UNAV (Navarre)

Read the article on the project’s kick-off meeting.

This project is co-financed at 65% by the European Regional Development Fund (ERDF) under the Interreg V-A Spain-France-Andorra POCTEFA Programme 2021–2027. The programme aims to strengthen the economic and social integration of the Spain-France-Andorra border area. Its support focuses on the development of cross-border economic, social, and environmental activities through joint strategies promoting sustainable territorial development.

poctefa
poctefa